Pharmacological treatment in moderate-to-severe Alzheimer's disease

Author： Hsiung Ging-Yuek Robin   Feldman Howard H  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.15, 2008-10, pp. : 2575-2582

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer’s disease?

By Doggrell Sheila  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 10, 2003-10 ,pp. : 1857-1860

Informa Healthcare

Access to resources Recommend Favorite

Memantine: A Pharmacoeconomic Review of its Use in Moderate-to-Severe Alzheimer's Disease

By Plosker Greg L.   Lyseng-Williamson Katherine A.  

PharmacoEconomics, Vol. 23, Iss. 2, 2005-01 ,pp. : 193-206

Adis International

Access to resources Recommend Favorite

Added Therapeutic Value of Memantine in the Treatment of Moderate to Severe Alzheimer's Disease

By Heinen-Kammerer T.   Rulhoff H.   Nelles S.   Rychlik R.  

Clinical Drug Investigation, Vol. 26, Iss. 6, 2006-01 ,pp. : 303-314

Adis International

Access to resources Recommend Favorite

The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimer's Disease

By Cappell Jaclyn   Herrmann Nathan   Cornish Stephen   Lanctôt Krista L.  

CNS Drugs, Vol. 24, Iss. 11, 2010-11 ,pp. : 909-927

Adis International

Access to resources Recommend Favorite

Spotlight on Memantine in Moderate to Severe Alzheimer's Disease†

By McKeage Kate  

Drugs & Aging, Vol. 27, Iss. 2, 2010-02 ,pp. : 177-179

Adis International

Access to resources Recommend Favorite